



### Société Générale – THE PREMIUM REVIEW 2012

# Profitable Growth.

Lead**Ing.** 

THE LINDE GROUP

29 November 2012 Georg Denoke CFO and Member of the Executive Board

### Disclaimer

This presentation contains forward-looking statements about Linde AG ("Linde") and their respective subsidiaries and businesses. These include, without limitation, those concerning the strategy of an integrated group, future growth potential of markets and products, profitability in specific areas, the future product portfolio, development of and competition in economies and markets of the group.

These forward looking statements involve known and unknown risks, uncertainties and other factors, many of which are outside of Linde's control, are difficult to predict and may cause actual results to differ significantly from any future results expressed or implied in the forward-looking statements on this presentation.

While Linde believes that the assumptions made and the expectations reflected on this presentation are reasonable, no assurance can be given that such assumptions or expectations will prove to have been correct and no guarantee of whatsoever nature is assumed in this respect. The uncertainties include, inter alia, the risk of a change in general economic conditions and government and regulatory actions. These known, unknown and uncertain factors are not exhaustive, and other factors, whether known, unknown or unpredictable, could cause the group's actual results or ratings to differ materially from those assumed hereinafter. Linde undertakes no obligation to update or revise the forward-looking statements on this presentation whether as a result of new information, future events or otherwise.

# Agenda



### 1. Operational and Financial Performance

- 2. Strategic Focus:
  - Growth Markets
  - Energy / Environment
  - Healthcare
- 3. Outlook

### Appendix



### Highlights

Group sales increased by 8.4% to € 11,063 m including a contribution of € 231 m of Lincare Group operating profit\* grew by 8.5% to € 2,563 m Group margin slightly improved by 10 bp to 23.2% EPS increased by 2.6% to € 5.15 EPS adjusted for the BOC purchase price allocation increased by 2.1% to € 5.80 Acquisition of Lincare successfully closed on 8 August 2012

### **Operations**

Operating profit margin with 27.1% almost on the level of last year (-20 bp) Highest growth rates in growth markets but overall more challenging environment HPO exceeded gross cost savings of € 700 m


### **Outlook confirmed & HPO continuation**

2012: Growth in sales and operating profit vs. record year 2011 HPO continuation: € 750 – 900 m of gross cost savings in 2013-2016

# **Group, sales by Divisions** Growth supported by Lincare acquisition

# THE LINDE GROUP





### **Gases Division**


- Growth supported by contribution of newly acquired Healthcare company Lincare
- Comparable growth\* of 3.3% also positively impacted by decaptivations and start up of tonnage plants

### **Engineering Division**

- Strong order intake in particular from Asia/Pacific and North America
- Order backlog further increased to € 3.9 bn and order intake significantly higher

# **Group, operating profit by Divisions** Group margin stabilised

# THE LINDE GROUP



### **Gases Division**

 Operating profit\* further increased supported by Lincare

### **Engineering Division**

- Operating margin of 12.3% on high level
- Margin development driven by successful execution of individual projects


### Other/Cons.

 2011 was influenced by a positive one-time effect due to changes made to the UK pension plan (€ 16 m)

# **Gases Division, sales by product areas** Solid performance in a more challenging environment



in € million, comparable\* (consolidated)



### Healthcare

Including € 231 m of Lincare, the growth rate is 38.6% in Healthcare

### Tonnage

Adjusted for the negative impacts from plant shut downs comparable growth would be 6.0%, including joint ventures 7.4%

### Bulk & Cylinder

Softer volume development visible

### 9M 2011


9M 2012

\*excluding currency, natural gas price effect and Lincare

\*\* due to changed reporting structure of around € 390 m are shifted from Cylinder to Bulk

## Gases Division, sales and operating profit by operating segment Growth continued





\*excluding currency, natural gas price effect and Lincare

# **Engineering Division, key figures** Order intake and backlog further increased



- Order intake of around USD 600 m for equipment/gas processing plants for shale gas
- Project wins in Tonnage support order intake and backlog
- Air separation and natural gas plants account for more than half of the order intake




\*EBITDA incl. share of profit or loss from associates and joint ventures

# **Group, solid financial position** A year of significant investments



### Lincare acquisition: Refinancing activities

- € 3.6 bn acquisition facility already reduced to slightly below € 1 bn
- Take-out measures include € 1.4 bn capital increase and two debt capital markets transactions totaling around € 1.3 bn




### **Credit Ratings**

- Standard&Poor's: A/A-1 with stable outlook (02 November 2012\*)
- Moody's: A3/P-2 with stable outlook (16 November 2012\*)

\* date of latest rating agency publication

Business Performance HPO 2013 - 2016: € 750 – 900 m additional gross cost savings **C** THE LINDE GROUP

- HPO 2009 to 2012: Fully on track and already within the target range
- HPO 2013 to 2016: Further continuation of the standardisation and optimisation processes within an extended footprint



### Accumulated gross cost savings in € million

# **Group, dividends** Dividend increased by 13.6% to € 2.50





\* comparable change: prior year figures including twelve months of BOC

# Agenda




- 1. Operational and Financial Performance
- 2. Strategic Focus:
  - Growth Markets
  - Energy / Environment
  - Healthcare
- 3. Outlook

### Appendix

# **Mega-trends** Leveraging growth with our Gases & Engineering set-up






# Mega-trend Growth Markets Strong investments in future growth



Growth Markets exposure further increased

Growth Market sales (% of Gases sales)




Majority of Capex 2011 invested in Growth Markets Gases Capex 2007 – 2011 in € bn



# **Mega-trend Growth Markets** Market leader in 4 out of 5 Growth Markets





Source: Linde database, figures excl. Japan, equipment, healthcare and major impact out of future growth markets of the energy/environment sector

# Gases Division, project pipeline Currently € 2.6 billion under execution



- € 4.7 bn investments between 2009-2015 (thereof € 0.6 bn in JVs @ share)
- Project amount for 2013 to 2015 increased by around € 650 m
- Around 70% of total project-capex allocated to Growth Markets
- Amount of project opportunities remains at € 4.3 bn on a high level




Project amount by on-stream date (incl. JVs) in € m

# Mega-trend Growth Markets

### Comprehensive strategy to capture growth potential in Asia



### Consolidated sales in Asia in € m



### Major investment commitments in Asia LTM

#### Yantai, China (Q3/2011)

- On-site supply contract with Wanhua Polyurethanes Co., Ltd.
- Two large scale ASUs: ~€ 130 m capex, on-stream date 2013/2014\*

#### Wu'an, China (Q4/2011)

- On-site supply contract with Hebei Puyang Iron and Steel Ltd.
- Decaptivation of 7 ASUs with energy efficiency upgrade and construction of a new ASU: ~ € 120 m capex, on-stream date 2014\*

#### Jilin, China (Q4/2011)

- On-site supply contract with Evonik Industries and Jilshen
- Hydrogen plant (SMR): ~€ 42 m capex, on-stream date 2013/2014\*

#### Dalian, China (Q1/2012):

- On-site supply contract with chemical producer Dahua Group
- Decaptivation of 2 ASUs: investment ~ € 70 m, on-stream date 2014\*

#### Kalinganagar, India (Q2/2012)


- On-site supply contract with Tata Steel,
- Two large scale ASUs: ~€ 80 m capex, on-stream date 2014\*

#### Ba Ria, Vietnam (Q3/2012)

- On-site supply contract with POSCO SS-Vina,
- Largest ASU in Vietnam: ~€ 40 m capex, on-stream date 2014\*
- \* to be expected


# **Mega-trend Energy/Environment** Importance of new technologies & industrial gases applications





- Fossil resources remain dominant energy source
- Fossil resources becoming scarce
- CO<sub>2</sub>-emissions steadily increasing
- Importance of renewable energy increasing but still limited reach


\*in quadrillion British Thermal Units (equals around 10<sup>27</sup> Joules)



(Please find assumptions for estimates on page 50)

# Mega-trend Energy/Environment Opportunities in shale gas business: Example US





### Engineering

- Total order intake since 2010 more than USD 1.1 bn
- Opportunities within the field of shale gas:
  - Natural gas processing plants: driven by the necessity of gas treatment for pipeline and bulk use
  - Small-mid-scale LNG plants: driven by increasing demand for merchant LNG
  - Ethane crackers: driven by increasing chemical production
  - Gases-to-liquids (GTL)


### Gases

- Potential leverage of our operation experience into the area of shale gas
- Based on shale gas new chemical clusters develop with the need for industrial gases supply

# Mega-trend Healthcare Market leader in an attractive industry



Relevant Healthcare growth areas 2011 vs. 2020 in € bn, Linde market position





### Market environment

Growing, ageing population and under-diagnosed diseases

Increasing wealth in Growth Markets

Healthcare budget pressure and regulation

# THE LINDE GROUP

### Development of new therapies and applications

### **Hospital Care**

- Gas supply and technical assistance
- Logistics and installation
- Customer service
- Hospital & medical gas services

### Gas Therapies

- Pulmonary hypertension & cardio-thoracic surgery
- Oxygen & heliox therapies
- Pain relief

### Intermediate Care

 REMEO: treatment and care of chronic patients with mechanical ventilation needs

### Homecare

- Home oxygen therapies
- Ventilation
- Sleep therapy
- Nutrition/Infusion
- INR monitoring
- Specialty pharmaceutical services









# Agenda




- 1. Operational and Financial Performance
- 2. Strategic Focus:
  - Growth Markets
  - Energy / Environment
  - Healthcare
- 3. Outlook

### Appendix

## Gases, Capex Development Capex Sales Ratio 2007-2011





24

# **Outlook\*** Profitable Growth.



2012	Group	<ul> <li>Growth in sales and operating profit vs. 2011</li> <li>Confirmation of HPO-programme 2009-2012: € 650-800 m of gross cost savings</li> </ul>
	Gases	<ul> <li>— Sales increase vs. 2011</li> <li>— Continuous improvement of productivity</li> </ul>
	Engineering	<ul> <li>Sales at the same level as in 2011</li> <li>Operating margin of at least 10%</li> </ul>

Mid-term	Group	<ul> <li>— 2013: Operating profit of at least € 4 bn</li> <li>— 2015: Adjusted** ROCE of 14% or above</li> <li>— Continuation of HPO-programme 2013-2016: € 750-900 m of gross cost savings</li> </ul>
	Gases	<ul> <li>Average capex/sales ratio 13% plus</li> <li>Revenue increase above market growth</li> <li>Further increase in productivity</li> </ul>



# Your questions are welcome.



# Agenda



- 1. Operational and Financial Performance
- 2. Strategic Focus:
  - Growth Markets
  - Energy / Environment
  - Healthcare
- 3. Outlook

### Appendix

# **Group, Q3 2012** Key P&L items



in € million	Q3 2011	Q3 2012	Δ in %
Revenue	3,435	3,889	13.2
Operating profit	804	908	12.9
Operating margin	23.4%	23.3%	-10 bp
EBIT	481	494	2.7
PPA depreciation	-60	-59	1.7
EBIT before PPA depreciation	541	553	2.2
Financial result	-89	-77	13.5
Taxes	-87	-90	-3.4
Net income	305	327	7.2
Net income – attributable to Linde AG shareholders	290	313	7.9
EPS in €	1.70	1.70	0.0
Adjusted EPS in €	1.89	1.89	0.0

# **Group, 9M 2012** Key P&L items



in € million	9M 2011	9M 2012	∆ in %
Revenue	10,209	11,063	8.4
Operating profit	2,363*	2,563	8.5
Operating margin	23.1	23.2	10 bp
EBIT	1,399	1,467	4.9
PPA depreciation	-181	-181	-
EBIT before PPA depreciation	1,580	1,648	4.3
Financial result	-215**	-240	-11.6
Taxes	-281	-269	4.3
Net income	903	958	6.1
Net income – attributable to Linde AG shareholders	856	904	5.6
EPS in €	5.02	5.15	2.6
Adjusted EPS in €	5.68	5.80	2.1

\*\*including positive one-time effect of € 30 m (repayment of BOC Edwards vendor loan)

# **Group, FY 2011** Key P&L items



in € million	2010	2011	Δ in %
Sales	12,868	13,787	7.1
Operating Profit	2,925	3,210	9.7
Margin	22.7%	23.3%	+60 bp
EBIT before PPA depreciation	1,933	2,152	11.3
PPA depreciation	-254	-242	5.0
EBIT	1,679	1,910	13.8
Financial Results	-280	-291	-3.9
Taxes	-335	-375	-11.9
Net income	1,064	1,244	16.9
Net income – Part of shareholders Linde AG	1,005	1,174	16.8
EPS in €	5.94	6.88	15.8
Adjusted EPS in €	6.89	7.71	11.9




EMEA (€ m)	Q1 2011	Q1 2012	Q2 2011	Q2 2012	Q3 2011	Q3 2012
Sales	1,393	1,445	1,431	1,499	1,434	1,528
Operating profit*	395	414	412	420	408	431
Operating margin	28.4%	28.7%	28.8%	28.0%	28.5%	28.2%
Asia/Pacific (€ m)	Q1 2011	Q1 2012	Q2 2011	Q2 2012	Q3 2011	Q3 2012
Sales	707	808	766	866	810	937
Operating profit*	196	218	210	235	228	244
Operating margin	27.7%	27.0%	27.4%	27.1%	28.1%	26.0%
Americas (€ m)	Q1 2011	Q1 2012	Q2 2011	Q2 2012	Q3 2011	Q3 2012
Sales	580	625	593	636	605	889
Operating profit*	136	152	134	160	135	210
Operating margin	23.4%	24.3%	22.6%	25.2%	22.3%	23.6%

\*EBITDA incl. share of profit or loss from associates and joint ventures

# **Group** Financial key indicators again on record levels

### Profitable growth for our shareholders

- adjusted EPS up by 11.9%
- adjusted ROCE further improved by 50 bp



THE LINDE GROUP

# **Group** Financial Result and Tax Rate



Financial Result (in € m) **Tax Rate** 23.9% 23.2% 22.9% 22.1% 

# **Group, 9M 2012** Cash Flow Statement



in € million	Q1 2012	Q2 2012	Q3 2012	9M 2012	9M 2011
Operating profit	808	847	908	2,563	2,363
Change in Working Capital	-318	-101	-42	-461	-114
Other changes	-105	-262	-229	-596	-550
Operating Cash Flow	385	484	637	1,506	1,699
Investments in tangibles/intangibles	-321	-384	-452	-1,157	-893
Acquisitions/Financial investments	-3	-655	-2,341	-2,999	-55
Other	43	24	42	109	116
Investment Cash Flow	-281	-1,015*	-2,751*	-4,047*	-832*
Free Cash Flow before Financing	104	-531	-2,114	-2,541	867
Interests and swaps, Dividends	-68	-592	-140	-800	-685
Capital increase			1,391	1,391	
Other changes	-33	44	-463	-452	9
Net debt increase (+)/decrease (-)	-3	1,079	1,326	2,402	-191

\*excluding proceeds on disposal of securities € 553 m in Q2 2012; € 298 m in Q3 2012; and payments for investments in securities € -600 m in 9M 2011

# **Group, FY 2011** Cash Flow Statement



	Q2 2011	Q3 2011*	Q4 2011*	2011*	2010
761	798	804	847	3,210	2,925
-180	6	60	39	-75	84
-141	-267	-142	-159	-709	-587
440	537	722	727	2,426	2,422
-237	-310	-346	-452	-1,345	-1,192
-13	-1	-41	-23	-78	-68
43	33	40	53	169	195
-207	-278	-347	-422	-1,254	-1,065
233	259	375	305	1,172	1,357
-45	-114	-123	-56	-338	-298
-2	-385	-7	-11	-405	-280
-186	240	-245	-238	-429	-779
	-180 -141 <b>440</b> -237 -13 43 -207 233 -45	761       798         -180       6         -141       -267         440       537         -237       -310         -13       -1         43       33         -207       -278         233       259         -45       -114         -2       -385	761       798       804         -180       6       60         -141       -267       -142         440       537       722         -237       -310       -346         -13       -1       -41         43       33       40         -207       -278       -347         233       259       375         -45       -114       -123         -2       -385       -7	761 $798$ $804$ $847$ $-180$ $6$ $60$ $39$ $-141$ $-267$ $-142$ $-159$ $440$ $537$ $722$ $727$ $-237$ $-310$ $-346$ $-452$ $-13$ $-1$ $-41$ $-23$ $43$ $33$ $40$ $53$ $-207$ $-278$ $-347$ $-422$ $233$ $259$ $375$ $305$ $-45$ $-114$ $-123$ $-56$ $-2$ $-385$ $-7$ $-11$	761 $798$ $804$ $847$ $3,210$ $-180$ $6$ $60$ $39$ $-75$ $-141$ $-267$ $-142$ $-159$ $-709$ $440$ $537$ $722$ $727$ $2,426$ $-237$ $-310$ $-346$ $-452$ $-1,345$ $-13$ $-1$ $-41$ $-23$ $-78$ $43$ $33$ $40$ $53$ $169$ $-207$ $-278$ $-347$ $-422$ $-1,254$ $233$ $259$ $375$ $305$ $1,172$ $-45$ $-114$ $-123$ $-56$ $-338$ $-2$ $-385$ $-7$ $-11$ $-405$

\* excluding investments in securities of  ${\bf \in 600}$  m in Q3 and  ${\bf \in 1,052}$  m in Q4

# **Group, solid financial position** Early refinancing of existing financial debt





### Continuous efforts to extend the Group's maturity profile

- Issuance of € 500 m 7 years senior notes in June 2012
- More than 80% of total financial debt is due beyond 2012
- Approx. 56% of total financial debt has a longer maturity than 5 years

### Balanced mix of various financing instruments

- Strong focus on long-term bond financing
- Strategic funding in EUR, GBP, USD and AUD





- Other Bonds
- Subordinated Bonds (\*callable in 2013/2016)
- Commercial Paper
- Bank Loans

Figures as of 31 December 2011


#### **Group, Pensions** Performance and key figures 2011




#### Net obligation

in € million	DBO	Plan asset	Net obligation
01/01/2011	4,971	4,467	504
Service costs	88		88
Net financing	253	254	-1
Actuarial losses/gains	335	153	182
Contributions/payments	-213	-13	-200
Other	-33	-19	-14
31/12/2011	5,401	4,842	559*

#### Pension plan assets portfolio structure



#### Performance of major pension plans




\* Figure does not include effects from asset ceiling (€ 26 m) and provisions for similar obligations (€ 26 m)

#### Gases Division, sales bridge 9M 2012 sales: price/volume increase of 3.3%



in € million




\*including  $\in$  113 m changes in consolidation

#### Gases Division Joint ventures




#### in € million

# **Proportionate Sales** (not incl. in the Group top-line)




#### Share of Net Income (contribution to operating profit)



# Gases Division, Split of Capex Growth Markets Capex increased to above 50 percent






#### 40

#### **Gases Division** From source to customer





# **Gases Division** Various distribution mix served from one product source





- 15-year take-or-pay contracts (incl. base facility fees)
- Add. growth in JVs & Embedded Finance Lease projects



- Multi-year contracts
- Application-driven





- Hospital care & Homecare
- Bulk & cylinder gases
- Structural growth




- High customer loyalty
- Includes specialty gases
- Cylinder rentals

# **Gases Division** Stability driven by a broad customer base




2011: Split of product areas by major end-customer groups



# 2011: Split of sales by major end-customer groups






#### **Gases Division, local business model** 70% of revenues come from a leading market position



# **Engineering Division** Leading market position in all segments





Supporting the energy/environmental mega-trend and leveraging customer relations for gas projects

# **Engineering Division** Key figures FY 2011






\*EBITDA incl. share of net income from associates and joint ventures


#### **Engineering Division** FY 2011 order intake by plant type and region



Order Intake by Plant Type



Order Intake by Region



### Mega-trend Growth Markets – China


A diverse customer portfolio to match an integrated business





### Mega-trend Growth Markets – China Integrated offer in selected industrial poles





# Clean Energy market estimation 2020 & 2030 top down



Market size in € bn	2015	2020	2030	Assumptions for 2030
Clean Coal			20 - 40	<ul> <li>Triple-digit number of 1 GW Carbon Capture (1.5 Gt/a CO<sub>2</sub> at EUR 25-40/t)</li> </ul>
CO <sub>2</sub> networks	small	1	15 - 25	<ul> <li>Installation of significant pipeline network and corresponding compression         <ul> <li>(1.5 Gt/a handling fee CO<sub>2</sub> at EUR 10-15/t)</li> </ul> </li> </ul>
H <sub>2</sub> fueling	small	1	10 - 15	<ul> <li>Installation of a significant fuel station infrastructure</li> <li>Corresponding annual H<sub>2</sub> consumption of some bn tons p.a.</li> </ul>
EOR/EGR*	1.5	4 - 5	18 - 35	<ul> <li>Single to double digit number of large N<sub>2</sub> EOR/NRU projects</li> <li>Double digit number of large CO<sub>2</sub> EOR projects including industrial CO<sub>2</sub> capture and pipeline (overlapping w/CCS)</li> </ul>
LNG	3 - 4	6 - 10	11 - 23	<ul> <li>Based on penetration rate of LNG replacing existing fuels</li> <li>Merchant LNG projects based on geographical set up and existing infrastructure</li> <li>Floating LNG projects</li> </ul>
Renewables	1	2	3	<ul> <li>Includes mainly gases used for manufacturing of photovoltaic cells</li> </ul>
Range	5 - 7	14 - 19	80 - 140	* Assuming 100% Build Own Operate and excluding sale of equipment and plants

General assumptions:

- Market numbers are directional only and w/o inflation or currency
- Oil price development at 80-100 USD/bll
- Outsourced gases market only (excl. captive market or equipment sales)

#### Mega-trend Healthcare

# Lincare – the performance leader in the Homecare industry



# 

- 1,091 locations
  - More than 800,000 patients
  - 35 Billing/Collections Offices
  - 31 Pharmacies
- 11,000 employees
  - 1,320 in Billing/Collections
  - 1,166 in Sales



#### Leading player in the US

- 2011: USD 1.8 bn sales and USD 454 m EBITDA
- Leading provider in the highly fragmented US industry
- Pure play in respiratory: ~90% of sales
- 28% of 2011 share of industry revenues
- National platform offers full US coverage
- Scale and efficiency advantages

#### Established brand with strong reputation


- High-quality products and services for patients and providers
- Top-class billing processes and IT-systems
- Strong sales force with superior relationships to referral sources

#### Best-in-class sales growth track record


- CAGR in 2002-2011 of 7.5%
- Managing price cuts through customer gains
- Disciplined industry consolidator utilizing strong cash flow

# **Mega-trend Healthcare** Lincare – Industry leader with balanced business & payor mix

THE LINDE GROUP



Source: Lincare investor presentation




### **Mega-trend Healthcare** Lincare – Ageing population & service duration in the US





- Development of depreciation and amortisation
- Impact in 9M 2012: € 181 million
- Expected range adjusted due to exchange rate effects



54

## Group, definition of financial key figures



Operating Profit	Return	EBITDA (incl. IFRIC 4 adjustment) excl. finance costs for pensions excl. special items incl. share of net income from associates and joint ventures
adjusted ROCE	Return	Operating profit - depreciation / amortisation excl. depreciation/amortization from purchase price allocation*
	Average Capital Employed	equity (incl. minorities) + financial debt + liabilities from finance leases + net pension obligations - cash, cash equivalents and securities - receivables from finance leases
adjusted EPS	Return	earnings after tax and minority interests + depreciation/amortization from purchase price allocation* +/- special items
	Shares	average outstanding shares

\*adjustment for the effects of the purchase price allocation on the acquisition of BOC only

#### **Investor Relations**



#### Contact

Phone:+49 89 357 57 1321eMail:investorrelations@linde.comInternet:www.linde.com

#### **Financial Calendar**

- Full year report 2012: 07 March 2013
- Q1 report 2013: 06 May 2013
- Annual General Meeting: 29 May 2013